ABSTRACT: Anticancer therapeutic intervention in patients with solid tumours still relies on the necessity of empirically treating many patients to obtain benefit for a limited few. The activity of a given drug in patients with advanced cancer is the result of a pharmacodynamic interaction with a pathway. Such putative pathways must be both prevalent in the cancer cells and relevant to the process of uncontrolled cell proliferation. Several examples have clearly demonstrated the value of measuring the molecular target and using it as inclusion criteria for clinical trials. Adaptive trial designs and the definition of clinical surrogate end-points can be helpful tools to further improve clinical drug development.
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Many molecularly targeted anticancer agents have demonstrated limited effectiveness thus far. An example is the marginal impact on overall survival of erlotinib (Tarceva Ò ), an epidermal growth factor receptor inhibitor, after first-or second-line treatment, compared to placebo. The respective study involved 731 patients with advanced non-small-cell lung cancer (NSCLC).
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After adjusting for stratification factors and epidermal growth factor receptor (EGFR) status, the survival curves for the two treatments started to diverge after 2 or 3 months. At 1 year, 31% of patients treated with erlotinib were still alive, compared with 22% of those on placebo.
Similarly, new therapeutic schemes for treating hormonerefractory prostate cancer have shown only limited effects on overall survival. In one study involving 674 men, the median overall survival was 17.5 months in the group given docetaxel and estramustine, and 15.6 months in those given mitoxantrone and prednisone. The corresponding hazard ratio for death was 0.80. Methylation-dependent transcriptional silencing of 14-3-3r, a major G2-M checkpoint control gene, could be a new, independent prognostic factor for survival in NSCLC patients receiving platinum-based chemotherapy. Of note patients with advanced MRCL, treated with trabectedin and who had the type III FUS-CHOP fusion protein variant resulting from a translocation mutation (13% of patients in the study reported by Grosso et al.
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) were more likely to have disease progression than those with other FUS-CHOP translocations.
They also had much shorter median progression-free survival times. 9 The clinical impact of Trabectin in unselected pre-treated, non MRCL, soft tissue sarcoma patients have been also
reported. 10 The data showed a 19% rate of tumour response, with remissions noted in different sarcoma subtypes. Long-lasting tumour control was reported in 21% if patients studied. These findings support the conclusion that trabectin efficacy is not testricted to MRCL patients.
POTENTIAL ROLE OF DNA REPAIR MECHANISMS:
In experimental models the functionality of DNA repair mechanisms influences the cyctotoxicity of trabectin and, hence, its efficacy. 6 If either the nucleotide excision repair (NER) is proficient or the double-stranded break (DSB) repair mechanism is deficient, the cytotoxicity of trabectedin is generally increased. Schö ffski et al.
selected ERCC1 and XPD as key genes for NER and BRCA1 for DSB and characterised their mRNA expression levels as potential biomarkers for patient outcome in tumour tissues from advanced, pretreated sarcoma patients exposed to trabectedin. Proposed N based on a relative risk > 30% for the target population in heavily pretreated cases and harbouring gene XXX methylation signature. + All patients screened for the signature. Results blinded. + Selection criteria based on clinical parameters. +
All Patients Treated
Analyse when the established number of events (e.g., disease progression) has been observed.
Open the signatures and correlate with outcome.
Conclusion: Agent ABC isactive in patients with advanced cancer bearing the XXX signature. Fig. 1 -A potential design for a phase II trial for a given drug in a particular tumour type based on a molecular signature.
